KBC Group NV reduced its position in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 54.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 50,566 shares of the medical instruments supplier’s stock after selling 60,936 shares during the quarter. KBC Group NV’s holdings in Insulet were worth $10,611,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in PODD. Norges Bank bought a new position in Insulet during the 4th quarter worth $300,794,000. RTW Investments LP bought a new position in Insulet during the fourth quarter worth about $92,264,000. AQR Capital Management LLC raised its stake in Insulet by 161.6% in the 4th quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock worth $130,499,000 after purchasing an additional 283,643 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Insulet by 712.1% in the 1st quarter. SG Americas Securities LLC now owns 318,848 shares of the medical instruments supplier’s stock valued at $66,907,000 after purchasing an additional 279,587 shares during the period. Finally, Worldquant Millennium Advisors LLC bought a new position in shares of Insulet during the second quarter worth approximately $80,082,000.
Insider Activity
In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.36% of the stock is owned by company insiders.
Key Stories Impacting Insulet
- Negative Sentiment: Multiple law firms announced or reminded investors about a recently filed securities fraud class action against Insulet, with claims tied to alleged misstatements about Omnipod safety and manufacturing practices. The filings cite two recalls affecting millions of pods and say the issues may have hurt investors who bought shares during the class period. Article Title
- Negative Sentiment: The lawsuit coverage suggests investors are still digesting the fallout from prior recalls and related stock declines, and firms are encouraging shareholders to seek lead-plaintiff roles before the August 31 deadline. Article Title
- Neutral Sentiment: One item noted that analysts still expect double-digit earnings growth ahead of Insulet’s next quarterly report, which provides a potential longer-term offset to the legal headlines. Article Title
Analyst Ratings Changes
PODD has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price target on the stock. Leerink Partners cut their target price on Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Canaccord Genuity Group dropped their price target on Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Stifel Nicolaus decreased their target price on shares of Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $235.25.
Read Our Latest Research Report on PODD
Insulet Stock Performance
NASDAQ:PODD opened at $158.93 on Thursday. The stock’s 50-day moving average is $153.58 and its 200-day moving average is $203.76. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The stock has a market cap of $11.01 billion, a P/E ratio of 36.96, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11.
Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.45 earnings per share for the current year.
Insulet Company Profile
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Stories
- Five stocks we like better than Insulet
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
